Background & Aims
Development of liver metastases is a frequent complication in patients with colorectal cancer (CRC), even after successful resection of the primary tumor. As such, post-operative adjuvant therapies that aim to eliminate residual disease after surgery may improve patient outcome.
We used a colon carcinoma liver metastases model, in which CC531s colon carcinoma cells are injected into the portal circulation by a surgical procedure. As injected tumor cells are arrested in the liver, this model is suitable for investigating the interaction of tumor cells with the liver microenvironment. By administering tumor specific monoclonal antibodies (mAb) directly post-operatively, we were able to determine the effect of antibody therapy on eradication of arrested tumor cells and subsequent liver metastases outgrowth.
We showed that post-operative treatment with tumor specific monoclonal antibodies (mAb) prevents liver metastases outgrowth. Antibody-dependent phagocytosis (ADPh) was the main mechanism involved, as enhanced uptake of tumor cells by innate mononuclear phagocytes in the liver was observed after mAb therapy. Furthermore, Kupffer cells (KC) were identified as the most prominent effector cells, as depletion of KC abolished therapeutic efficacy. This was partly compensated by monocytes when animals were treated with a high mAb dose, but monocytes were unable to phagocytose tumor cells when rats were treated with low mAb doses.
The finding that KC and monocytes can eliminate tumor cells through ADPh has important and promising clinical implications for designing new adjuvant therapies for patients undergoing CRC resection.
Abbreviations:ADCC (antibody dependent cellular cytotoxicity), ADPh (antibody dependent phagocytosis), CRC (colorectal cancer), FcγR (Fc gamma receptor), FCS (fetal calf serum), Ig (immunoglobulin), i.p. (intraperitoneal), KC (Kupffer cell), mAb (monoclonal antibody), NK (natural killer)
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to Journal of Hepatology
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
- Anti-β1 integrin antibody reduces surgery-induced adhesion of colon carcinoma cells to traumatized peritoneal surfaces.Ann Surg. 2008; 247: 85-94
- Excisional surgery for cancer cure: therapy at a cost.Lancet Oncol. 2003; 4: 760-768
- Blocking α2 integrins on rat CC531s colon carcinoma cells prevents operation-induced augmentation of liver metastases outgrowth.Hepatology. 2008; 47: 532-543
- Role of circulating tumour cells in predicting recurrence after excision of primary colorectal carcinoma.Br J Surg. 2007; 94: 96-105
- Significant detection of circulating cancer cells in the blood by reverse transcriptase-polymerase chain reaction during colorectal cancer resection.Ann Surg. 2000; 232: 58-65
- Biology of colorectal liver metastases: a review.J Surg Oncol. 2006; 94: 68-80
- Preoperative hepatic and regional arterial chemotherapy in the prevention of liver metastasis after colorectal cancer surgery.Ann Surg. 2007; 245: 583-590
- Prophylactic hepatic arterial infusion chemotherapy for the prevention of liver metastasis in patients with colon carcinoma: a randomized control trial.Cancer. 2004; 100: 590-597
- Monoclonal antibody therapy of cancer.Nat Biotechnol. 2005; 23: 1147-1157
- Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer.N Engl J Med. 2004; 351: 337-345
- Monoclonal antibody therapy for resected Dukes’ C colorectal cancer: seven-year outcome of a multicenter randomized trial.J Clin Oncol. 1998; 16: 1788-1794
- EpCAM an immunotherapeutic target for gastrointestinal malignancy: current experience and future challenges.Br J Cancer. 2007; 96: 1013-1019
- Structural basis for inhibition of the epidermal growth factor receptor by cetuximab.Cancer Cell. 2005; 7: 301-311
- Complement-mediated mechanisms in anti-GD2 monoclonal antibody therapy of murine metastatic cancer.Cancer Res. 2005; 65: 10562-10568
- Fc receptors are required in passive and active immunity to melanoma.Proc Natl Acad Sci USA. 1998; 95: 652-656
- Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma.J Clin Oncol. 2003; 21: 3940-3947
- Comparison of in vitro antibody-targeted cytotoxicity using mouse, rat and human effectors.Cancer Immunol Immunother. 2000; 49: 259-266
- Experimental antibody therapy of liver metastases reveals functional redundancy between FcγRI and FcγRIV.J Immunol. 2008; 181: 6829-6836
- The development of novel mouse monoclonal antibodies against the CC531 rat colon adenocarcinoma.Clin Exp Metastasis. 2000; 18: 281-289
- Membrane-bound complement regulatory proteins inhibit complement activation by an immunotherapeutic mAb in a syngeneic rat colorectal cancer model.Mol Immunol. 2003; 40: 13-23
- Murine monoclonal isotype switch variants. Detection with rat monoclonal antibodies in ELISA and isolation by sequential sublining.J Immunol Methods. 1988; 106: 195-202
- A model system for studies of colon carcinogenesis: tumor induction by a single injection of methylazoxymethanol acetate.J Natl Cancer Inst. 1974; 53: 1419-1421
- Survival of mononuclear phagocytes depends on a lineage-specific growth factor that the differentiated cells selectively destroy.Cell. 1982; 28: 71-81
- Depletion and repopulation of macrophages in spleen and liver of rat after intravenous treatment with liposome-encapsulated dichloromethylene diphosphonate.Cell Tissue Res. 1990; 260: 215-222
- Role of Kupffer cells in arresting circulating tumor cells and controlling metastatic growth in the liver.Hepatology. 1996; 23: 1224-1231
- Divergent immunoglobulin g subclass activity through selective Fc receptor binding.Science. 2005; 310: 1510-1512
- The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy.J Exp Med. 2004; 199: 1659-1669
- Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin).Semin Oncol. 1999; 26: 60-70
- Natural killer (NK) cell function is a strong prognostic factor in colorectal carcinoma patients treated with the monoclonal antibody 17-1A.Int J Cancer. 2003; 105: 717-723
- Elements related to heterogeneity of antibody-dependent cell cytotoxicity in patients under trastuzumab therapy for primary operable breast cancer overexpressing Her2.Cancer Res. 2007; 67: 11991-11999
- Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets.Nat Med. 2000; 6: 443-446
- The high-affinity IgG receptor, FcγRI, plays a central role in antibody therapy of experimental melanoma.Cancer Res. 2006; 66: 1261-1264
- FcγRIV: a novel FcR with distinct IgG subclass specificity.Immunity. 2005; 23: 41-51
- Signaling events involved in anti-CD20-induced apoptosis of malignant human B cells.Cancer Immunol Immunother. 2000; 48: 673-683
- Interactions between rat colon carcinoma cells and Kupffer cells during the onset of hepatic metastasis.Int J Cancer. 2004; 112: 793-802
- Role of lung-marginated monocytes in an in vivo mouse model of ventilator-induced lung injury.Am J Respir Crit Care Med. 2009; 179: 914-922
- Immune-stimulating effects of low-dose perioperative recombinant granulocyte–macrophage colony-stimulating factor in patients operated on for primary colorectal carcinoma.Br J Surg. 2001; 88: 539-544
- Enhanced killing capacity of human Kupffer cells after activation with human granulocyte/macrophage-colony-stimulating factor and interferon gamma.Cancer Immunol Immunother. 1994; 39: 179-184
Published online: June 25, 2010
© 2010 European Association for the Study of the Liver. Published by Elsevier Inc. All rights reserved.